ISSN 1725-2423
Official Journal
of the European Union
C 73
English edition
Information and Notices
Volume 52
27 March 2009
|
ISSN 1725-2423 |
||
|
Official Journal of the European Union |
C 73 |
|
|
|
||
|
English edition |
Information and Notices |
Volume 52 |
|
Notice No |
Contents |
page |
|
|
II Information |
|
|
|
INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
|
|
|
Commission |
|
|
2009/C 073/01 |
Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections ( 1 ) |
|
|
|
IV Notices |
|
|
|
NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
|
|
|
Commission |
|
|
2009/C 073/02 |
||
|
2009/C 073/03 |
||
|
2009/C 073/04 |
||
|
|
V Announcements |
|
|
|
ADMINISTRATIVE PROCEDURES |
|
|
|
Commission |
|
|
2009/C 073/05 |
||
|
|
PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY |
|
|
|
Commission |
|
|
2009/C 073/06 |
||
|
|
OTHER ACTS |
|
|
|
Commission |
|
|
2009/C 073/07 |
||
|
|
Corrigenda |
|
|
2009/C 073/08 |
||
|
|
|
|
|
(1) Text with EEA relevance |
|
EN |
|
II Information
INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES
Commission
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/1 |
Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty
Cases where the Commission raises no objections
(Text with EEA relevance)
(2009/C 73/01)
|
Date of adoption of the decision |
23.12.2008 |
||||
|
Reference number of the aid |
N 143/08 |
||||
|
Member State |
Slovakia |
||||
|
Region |
Stredné Slovensko |
||||
|
Title (and/or name of the beneficiary) |
ZSNP, a.s. |
||||
|
Legal basis |
Zákon č. 587/2004 Z. z. o Environmentálnom fonde a o zmene a doplnení niektorých zákonov v znení neskorších predpisov; Vyhláška Ministerstva životného prostredia Slovenskej republiky č. 157/2005 Z. z., ktorou sa vykonáva zákon č. 587/2004 Z. z. o Environmentálnom fonde a o zmene a doplnení niektorých zákonov; Zákon č. 231/1999 Z. z. o štátnej pomoci v znení neskorších predpisov |
||||
|
Type of measure |
Individual aid |
||||
|
Objective |
Environmental protection |
||||
|
Form of aid |
Soft loan |
||||
|
Budget |
Overall budget: SKK 65,8 million |
||||
|
Intensity |
12 % |
||||
|
Duration |
— |
||||
|
Economic sectors |
Manufacturing industry |
||||
|
Name and address of the granting authority |
|
||||
|
Other information |
— |
The authentic text(s) of the decision, from which all confidential information has been removed, can be found at:
http://ec.europa.eu/community_law/state_aids/
|
Date of adoption of the decision |
24.2.2009 |
|
Reference number of the aid |
N 77/09 |
|
Member State |
Hungary |
|
Region |
— |
|
Title (and/or name of the beneficiary) |
Limited amounts of compatible aid |
|
Legal basis |
Art. 23/A, 23/C and 23/D. of the Government Decree 85/2004. (IV. 19.) on the Procedure regarding State Aid defined by Article 87 (1) of the EC Treaty and on the Regional Aid Map |
|
Type of measure |
Individual aid |
|
Objective |
Aid to remedy serious disturbances in the economy |
|
Form of aid |
Ad hoc contracts |
|
Budget |
— |
|
Intensity |
— |
|
Duration |
22.2.2009-31.12.2010 |
|
Economic sectors |
All sectors |
|
Name and address of the granting authority |
All competent aid granting authorities in the Hungary |
|
Other information |
— |
The authentic text(s) of the decision, from which all confidential information has been removed, can be found at:
http://ec.europa.eu/community_law/state_aids/
|
Date of adoption of the decision |
24.2.2009 |
|
Reference number of the aid |
N 78/09 |
|
Member State |
Hungary |
|
Region |
— |
|
Title (and/or name of the beneficiary) |
Temporary aid scheme for granting aid in the form of loans with subsidised interest rate |
|
Legal basis |
Art. 23/B, Art. 23/C and Art. 23/D of the Government Decree 85/2004. (IV. 19.) on the Procedure regarding State Aid defined by Article 87 (1) of the EC Treaty and on the Regional Aid Map |
|
Type of measure |
Individual aid |
|
Objective |
Aid to remedy serious disturbances in the economy |
|
Form of aid |
Ad hoc contracts |
|
Budget |
— |
|
Intensity |
— |
|
Duration |
23.2.2009-31.12.2010 |
|
Economic sectors |
All sectors |
|
Name and address of the granting authority |
All competent aid granting authorities in Hungary |
|
Other information |
— |
The authentic text(s) of the decision, from which all confidential information has been removed, can be found at:
http://ec.europa.eu/community_law/state_aids/
IV Notices
NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES
Commission
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/4 |
Euro exchange rates (1)
26 March 2009
(2009/C 73/02)
1 euro=
|
|
Currency |
Exchange rate |
|
USD |
US dollar |
1,3607 |
|
JPY |
Japanese yen |
133,63 |
|
DKK |
Danish krone |
7,4488 |
|
GBP |
Pound sterling |
0,9316 |
|
SEK |
Swedish krona |
10,8765 |
|
CHF |
Swiss franc |
1,5266 |
|
ISK |
Iceland króna |
|
|
NOK |
Norwegian krone |
8,8175 |
|
BGN |
Bulgarian lev |
1,9558 |
|
CZK |
Czech koruna |
27,233 |
|
EEK |
Estonian kroon |
15,6466 |
|
HUF |
Hungarian forint |
302 |
|
LTL |
Lithuanian litas |
3,4528 |
|
LVL |
Latvian lats |
0,7095 |
|
PLN |
Polish zloty |
4,5675 |
|
RON |
Romanian leu |
4,2655 |
|
TRY |
Turkish lira |
2,255 |
|
AUD |
Australian dollar |
1,9349 |
|
CAD |
Canadian dollar |
1,6707 |
|
HKD |
Hong Kong dollar |
10,4579 |
|
NZD |
New Zealand dollar |
2,3497 |
|
SGD |
Singapore dollar |
2,0349 |
|
KRW |
South Korean won |
1 810,75 |
|
ZAR |
South African rand |
12,7498 |
|
CNY |
Chinese yuan renminbi |
9,2191 |
|
HRK |
Croatian kuna |
7,4682 |
|
IDR |
Indonesian rupiah |
15 797,73 |
|
MYR |
Malaysian ringgit |
4,8909 |
|
PHP |
Philippine peso |
65,53 |
|
RUB |
Russian rouble |
45,4005 |
|
THB |
Thai baht |
47,627 |
|
BRL |
Brazilian real |
3,0426 |
|
MXN |
Mexican peso |
19,2525 |
|
INR |
Indian rupee |
68,246 |
Source: reference exchange rate published by the ECB.
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/5 |
Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 February 2009 to 28 February 2009
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) )
(2009/C 73/03)
— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
|||||
|
4.2.2009 |
Nplate |
Romiplostim |
|
EU/1/08/497/001-002 |
Powder for solution for injection |
B02BX04 |
6.2.2009 |
|||||
|
6.2.2009 |
Zarzio |
Filgrastim |
|
EU/1/08/495/001-008 |
Solution for injection or infusion |
L03AA02 |
10.2.2009 |
|||||
|
6.2.2009 |
Filgrastim Hexal |
Filgrastim |
|
EU/1/08/496/001-008 |
Solution for injection or infusion |
L03AA02 |
10.2.2009 |
|||||
|
17.2.2009 |
FIRMAGON |
Degarelix (as acetate) |
|
EU/1/08/504/001-002 |
Powder and solvent for solution for injection |
L02BX02 |
19.2.2009 |
|||||
|
19.2.2009 |
Thymanax |
Agomelatine |
|
EU/1/08/498/001-008 |
Film-coated tablet |
NO6AX22 |
23.2.2009 |
|||||
|
19.2.2009 |
Opgenra |
Eptotermin alfa |
|
EU/1/08/489/001 |
Powders for suspension for implantation |
M05BC02 |
23.2.2009 |
|||||
|
19.2.2009 |
Valdoxan |
Agomelatine |
|
EU/1/08/499/001-008 |
Film-coated tablet |
NO6AX22 |
23.2.2009 |
|||||
|
24.2.2009 |
FABLYN |
Lasofoxifene |
|
EU/1/08/500/001-004 |
Film-coated tablet |
Non applicable |
26.2.2009 |
|||||
|
24.2.2009 |
INTANZA |
Influenza Vaccine (split virion, inactivated) |
|
EU/1/08/505/001-006 |
Suspension for injection |
J07BB02 |
26.2.2009 |
|||||
|
24.2.2009 |
IDflu |
Influenza Vaccine (split virion, inactivated) |
|
EU/1/08/507/001-006 |
Suspension for injection |
J07BB02 |
26.2.2009 |
|||||
|
25.2.2009 |
Efient |
Prasugrel |
|
EU/1/08/503/001-014 |
Film-coated tablet |
Non applicable |
27.2.2009 |
— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
|||||||
|
2.2.2009 |
Vfend |
|
EU/1/02/212/001-026 |
5.2.2009 |
|||||||
|
2.2.2009 |
Gardasil |
|
EU/1/06/357/001-021 |
4.2.2009 |
|||||||
|
2.2.2009 |
Silgard |
|
EU/1/06/358/001-021 |
4.2.2009 |
|||||||
|
2.2.2009 |
Vimpat |
|
EU/1/08/470/001-016 |
4.2.2009 |
|||||||
|
2.2.2009 |
DuoTrav |
|
EU/1/06/338/001-003 |
4.2.2009 |
|||||||
|
4.2.2009 |
Elaprase |
|
EU/1/06/365/001-003 |
6.2.2009 |
|||||||
|
6.2.2009 |
REYATAZ |
|
EU/1/03/267/001-010 |
10.2.2009 |
|||||||
|
6.2.2009 |
Extavia |
|
EU/1/08/454/001-004 |
10.2.2009 |
|||||||
|
10.2.2009 |
Pradaxa |
|
EU/1/08/442/001-008 |
12.2.2009 |
|||||||
|
10.2.2009 |
SUTENT |
|
EU/1/06/347/001-006 |
12.2.2009 |
|||||||
|
10.2.2009 |
Baraclude |
|
EU/1/06/343/001-007 |
12.2.2009 |
|||||||
|
10.2.2009 |
Sprycel |
|
EU/1/06/363/001-011 |
12.2.2009 |
|||||||
|
10.2.2009 |
Xolair |
|
EU/1/05/319/005- 010 |
12.2.2009 |
|||||||
|
10.2.2009 |
TachoSil |
|
EU/1/04/277/001-004 |
12.2.2009 |
|||||||
|
10.2.2009 |
Abraxane |
|
EU/1/07/428/001 |
13.2.2009 |
|||||||
|
10.2.2009 |
Arava |
|
EU/1/99/118/001-010 |
12.2.2009 |
|||||||
|
10.2.2009 |
IVEMEND |
|
EU/1/07/437/001-002 |
12.2.2009 |
|||||||
|
11.2.2009 |
Zonegran |
|
EU/1/04/307/001-013 |
13.2.2009 |
|||||||
|
13.2.2009 |
Clopidogrel Winthrop |
|
EU/1/08/465/001 EU/1/08/465/003 EU/1/08/465/005 EU/1/08/465/007 EU/1/08/465/009 EU/1/08/465/011 EU/1/08/465/013 EU/1/08/465/018-019 |
17.2.2009 |
|||||||
|
13.2.2009 |
Clopidogrel BMS |
|
EU/1/08/464/001 EU/1/08/464/003 EU/1/08/464/005 EU/1/08/464/007 EU/1/08/464/009 EU/1/08/464/011 EU/1/08/464/013 EU/1/08/464/018-019 |
17.2.2009 |
|||||||
|
13.2.2009 |
Dafiro |
|
EU/1/06/371/001-036 |
17.2.2009 |
|||||||
|
13.2.2009 |
Lyrica |
|
EU/1/04/279/001-043 |
17.2.2009 |
|||||||
|
13.2.2009 |
Copalia |
|
EU/1/06/372/001-036 |
17.2.2009 |
|||||||
|
13.2.2009 |
Exforge |
|
EU/1/06/370/001-036 |
17.2.2009 |
|||||||
|
13.2.2009 |
Tasmar |
|
EU/1/97/044/001-008 |
18.2.2009 |
|||||||
|
|||||||||||
|
13.2.2009 |
Imprida |
|
EU/1/06/373/001-036 |
17.2.2009 |
|||||||
|
17.2.2009 |
Temodal |
|
EU/1/98/096/001-022 |
19.2.2009 |
|||||||
|
19.2.2009 |
Zerene |
|
EU/1/99/099/001-006 |
23.2.2009 |
|||||||
|
19.2.2009 |
Insuman |
|
EU/1/97/030/170-189 |
23.2.2009 |
|||||||
|
19.2.2009 |
Sonata |
|
EU/1/99/102/001-006 |
23.2.2009 |
|||||||
|
19.2.2009 |
Insulin Human Winthrop |
|
EU/1/06/368/143-162 |
23.2.2009 |
|||||||
|
20.2.2009 |
Myozyme |
|
EU/1/06/333/001-003 |
24.2.2009 |
|||||||
|
20.2.2009 |
Evoltra |
|
EU/1/06/334/001-004 |
24.2.2009 |
|||||||
|
20.2.2009 |
Luminity |
|
EU/1/06/361/001-002 |
24.2.2009 |
|||||||
|
20.2.2009 |
Bondenza |
|
EU/1/03/266/003-006 |
24.2.2009 |
|||||||
|
23.2.2009 |
Myozyme |
|
EU/1/06/333/001-003 |
25.2.2009 |
|||||||
|
23.2.2009 |
BeneFIX |
|
EU/1/97/047/001-007 |
25.2.2009 |
|||||||
|
23.2.2009 |
Bonviva |
|
EU/1/03/265/003-006 |
25.2.2009 |
|||||||
|
23.2.2009 |
Mabthera |
|
EU/1/98/067/001-002 |
25.2.2009 |
|||||||
|
24.2.2009 |
Thalidomide Celgene |
|
EU/1/08/443/001 |
26.2.2009 |
|||||||
|
24.2.2009 |
Irbesartan HCT BMS |
|
EU/1/06/369/001-028 |
26.2.2009 |
|||||||
|
24.2.2009 |
Viracept |
|
EU/1/97/054/004-005 |
26.2.2009 |
|||||||
|
24.2.2009 |
Revlimid |
|
EU/1/07/391/001-004 |
26.2.2009 |
|||||||
|
24.2.2009 |
Abilify |
|
EU/1/04/276/001-020 EU/1/04/276/024-036 |
26.2.2009 |
|||||||
|
25.2.2009 |
ORENCIA |
|
EU/1/07/389/001-003 |
27.2.2009 |
|||||||
|
25.2.2009 |
Dynastat |
|
EU/1/02/209/001-008 |
27.2.2009 |
|||||||
|
25.2.2009 |
Levitra |
|
EU/1/03/248/001-012 |
27.2.2009 |
|||||||
|
25.2.2009 |
Forsteo |
|
EU/1/03/247/001-002 |
27.2.2009 |
|||||||
|
25.2.2009 |
Zerit |
|
EU/1/96/009/001-009 |
27.2.2009 |
|||||||
|
25.2.2009 |
Irbesartan Winthrop |
|
EU/1/06/376/001-033 |
27.2.2009 |
|||||||
|
25.2.2009 |
HUMIRA |
|
EU/1/03/256/001-010 |
27.2.2009 |
|||||||
|
25.2.2009 |
Vivanza |
|
EU/1/03/249/001-012 |
27.2.2009 |
|||||||
|
25.2.2009 |
Advagraf |
|
EU/1/07/387/001-010 |
27.2.2009 |
|||||||
|
25.2.2009 |
Ranexa |
|
EU/1/08/462/001-012 |
27.2.2009 |
|||||||
|
|||||||||||
|
26.2.2009 |
Advate |
|
EU/1/03/271/001-006 |
2.3.2009 |
|||||||
|
26.2.2009 |
ReFacto AF |
|
EU/1/99/103/001-004 |
2.3.2009 |
|||||||
|
26.2.2009 |
Myfenax |
|
EU/1/07/438/001-004 |
2.3.2009 |
|||||||
|
26.2.2009 |
Fasturtec |
|
EU/1/00/170/001-002 |
2.3.2009 |
|||||||
|
26.2.2009 |
Mycophenolate mofetil Teva |
|
EU/1/07/439/001-004 |
2.3.2009 |
|||||||
|
26.2.2009 |
Pradaxa |
|
EU/1/08/442/001-008 |
2.3.2009 |
|||||||
|
26.2.2009 |
Protopic |
|
EU/1/02/201/001-006 |
4.3.2009 |
|||||||
|
26.2.2009 |
Volibris |
|
EU/1/08/451/001-004 |
2.3.2009 |
|||||||
|
26.2.2009 |
Telzir |
|
EU/1/04/282/001-002 |
2.3.2009 |
|||||||
|
26.2.2009 |
Xeristar |
|
EU/1/04/297/001-008 |
2.3.2009 |
|||||||
|
26.2.2009 |
Karvezide |
|
EU/1/98/085/001-034 |
2.3.2009 |
|||||||
|
26.2.2009 |
Karvea |
|
EU/1/97/049/001-039 |
2.3.2009 |
|||||||
|
26.2.2009 |
CoAprovel |
|
EU/1/98/086/001-034 |
2.3.2009 |
|||||||
|
26.2.2009 |
Oprymea |
|
EU/1/08/469/001-025 |
2.3.2009 |
|||||||
|
26.2.2009 |
Aprovel |
|
EU/1/97/046/001-039 |
2.3.2009 |
|||||||
|
26.2.2009 |
Tasigna |
|
EU/1/07/422/001-004 |
3.3.2009 |
|||||||
|
26.2.2009 |
Baraclude |
|
EU/1/06/343/001-007 |
3.3.2009 |
|||||||
|
26.2.2009 |
REYATAZ |
|
EU/1/03/267/001-010 |
3.3.2009 |
|||||||
|
26.2.2009 |
Sprycel |
|
EU/1/06/363/001-011 |
3.3.2009 |
|||||||
|
26.2.2009 |
Tyverb |
|
EU/1/07/440/001-002 |
3.3.2009 |
|||||||
|
26.2.2009 |
Xagrid |
|
EU/1/04/295/001 |
3.3.2009 |
|||||||
|
27.2.2009 |
Ariclaim |
|
EU/1/04/283/001-012 |
3.3.2009 |
— Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
|||||
|
10.2.2009 |
Loxicom |
Meloxicam |
|
EU/2/08/090/001-005 |
Oral Suspension |
QM01AC06 |
12.2.2009 |
|||||
|
EU/2/08/090/006-008 |
Solution for Injection |
|||||||||||
|
11.2.2009 |
STARTVAC |
Escherichia coli J5: > 50 RED60 Staph. Aureus (CP8): > 50 RED80 |
|
EU/2/08/092/001-007 |
Emulsion for injection |
QI02 AB |
13.2.2009 |
— Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||||
|
12.2.2009 |
Purevax RCCh |
|
EU/2/04/049/001-002 |
16.2.2009 |
||||
|
13.2.2009 |
Purevax RCP FeLV |
|
EU/2/04/048/001-002 |
17.2.2009 |
||||
|
13.2.2009 |
Purevax RCPCh FeLV |
|
EU/2/04/047/001-002 |
17.2.2009 |
||||
|
17.2.2009 |
Purevax RCPCh |
|
EU/2/04/050/001-002 |
19.2.2009 |
||||
|
17.2.2009 |
ProMeris Duo |
|
EU/2/06/065/001-010 |
19.2.2009 |
||||
|
17.2.2009 |
Purevax RC |
|
EU/2/04/051/001-002 |
20.2.2009 |
||||
|
17.2.2009 |
Purevax RCP |
|
EU/2/04/052/001-002 |
19.2.2009 |
— Suspension of a marketing authorization (Article 45 of Regulation (EC) No 726/2004)
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||||
|
20.2.2009 |
Porcilis Pesti |
|
EU/2/99/016/001-006 |
24.2.2009 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
The European Medicines Agency |
|
7, Westferry Circus |
|
Canary Wharf |
|
London E14 4HB |
|
UNITED KINGDOM |
(1) OJ L 136, 30.4.2004, p. 1.
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/16 |
Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 February 2009 to 28 February 2009
(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2) )
(2009/C 73/04)
— Issuing, maintenance or modification of a national marketing authorization
|
Date of the decision |
Name(s) of the medicinal product |
Holder(s) of the marketing authorization |
Member State concerned |
Date of notification |
||||||||||
|
4.2.2009 |
Nplate |
|
This Decision is addressed to the Member States |
6.2.2009 |
||||||||||
|
6.2.2009 |
Implanon |
See Annex I |
See Annex I |
9.2.2009 |
||||||||||
|
16.2.2009 |
Diovan |
See Annex II |
See Annex II |
17.2.2009 |
||||||||||
|
17.2.2009 |
FIRMAGON |
|
This Decision is addressed to the Member States |
18.2.2009 |
||||||||||
|
19.2.2009 |
Valdoxan |
|
This Decision is addressed to the Member States |
23.2.2009 |
||||||||||
|
19.2.2009 |
Opgenra |
|
This Decision is addressed to the Member States |
23.2.2009 |
||||||||||
|
19.2.2009 |
Thymanax |
|
This Decision is addressed to the Member States |
23.2.2009 |
||||||||||
|
24.2.2009 |
FABLYN |
|
This Decision is addressed to the Member States |
25.2.2009 |
||||||||||
|
25.2.2009 |
Ranexa |
|
This Decision is addressed to the Member States |
26.2.2009 |
||||||||||
|
25.2.2009 |
Efient |
|
This Decision is addressed to the Member States |
27.2.2009 |
||||||||||
|
26.2.2009 |
ReFacto AF |
|
This Decision is addressed to the Member States |
27.2.2009 |
(1) OJ L 311, 28.11.2001, p. 67.
(2) OJ L 311, 28.11.2001, p. 1.
ANNEX I
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION AND MARKETING AUTHORIZATION HOLDERS IN THE MEMBER STATES
|
Member State EU/EEA |
Marketing Authorization Holder |
Applicant |
(Invented) Name |
Strength |
Pharmaceutical form |
Route of administration |
||||||
|
Austria |
|
|
Implanon — Implantat |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Belgium |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Czech Republic |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Denmark |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Finland |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
France |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Germany |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Hungary |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Iceland |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Ireland |
|
|
Implanon 68 mg implant |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Italy |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Luxembourg |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Malta |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Netherlands |
|
|
Implanon 68 mg |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Norway |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Portugal |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Slovak Republic |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Spain |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
Sweden |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
||||||
|
United Kingdom |
|
|
Implanon |
68 mg |
Implant |
Subcutaneous use |
ANNEX II
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORIZATION HOLDERS IN THE MEMBER STATES
|
Member State EU/EEA |
Marketing Authorization Holder |
(Invented) Name |
Strength |
Pharmaceutical form |
Route of administration |
||||||
|
Austria |
|
Diovan 40 mg Filmtabletten |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Angiosan 40 mg Filmtabletten |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Diovan 80 mg Filmtabletten |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Angiosan 80 mg Filmtabletten |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Diovan 160 mg Filmtabletten |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Angiosan 160 mg Filmtabletten |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Diovan 320 mg Filmtabletten |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Austria |
|
Angiosan 320 mg Filmtabletten |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Diovane 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Novacard 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Diovane 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Novacard 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Diovane 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Novacard 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Diovane 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Belgium |
|
Novacard 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Bulgaria |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Bulgaria |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Bulgaria |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Cyprus |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Cyprus |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Cyprus |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Cyprus |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Czech Republic |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Czech Republic |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Denmark |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Denmark |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Denmark |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Denmark |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Estonia |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Estonia |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Estonia |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Estonia |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Finland |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Finland |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Finland |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Finland |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
France |
|
Tareg 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
France |
|
Tareg 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
France |
|
Tareg 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Cordinate 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Provas 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Cordinate 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Provas 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Cordinate 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Provas 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Cordinate 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Germany |
|
Provas 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Dalzad 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Dalzad 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Dalzad 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Dalzad 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Greece |
|
Diovan 80 mg |
80 mg |
Hard gelatine capsules |
Oral |
||||||
|
Greece |
|
Dalzad 80 mg |
80 mg |
Hard gelatine capsules |
Oral |
||||||
|
Greece |
|
Diovan 160 mg |
160 mg |
Hard gelatine capsules |
Oral |
||||||
|
Greece |
|
Dalzad 160 mg |
160 mg |
Hard gelatine capsules |
Oral |
||||||
|
Hungary |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Hungary |
|
Varexan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Hungary |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Hungary |
|
Varexan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Hungary |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Hungary |
|
Varexan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Hungary |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Iceland |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Iceland |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Iceland |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Iceland |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Ireland |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Ireland |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Ireland |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Ireland |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Tareg 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Rixil |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Tareg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Rixil |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Tareg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Rixil |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Italy |
|
Tareg |
80 mg |
Hard capsules |
Oral |
||||||
|
Italy |
|
Rixil |
80 mg |
Hard capsules |
Oral |
||||||
|
Italy |
|
Tareg |
160 mg |
Hard capsules |
Oral |
||||||
|
Italy |
|
Rixil |
160 mg |
Hard capsules |
Oral |
||||||
|
Latvia |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Latvia |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Latvia |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Latvia |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Lithuania |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Lithuania |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Lithuania |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Luxembourg |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Luxembourg |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Luxembourg |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Luxembourg |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Malta |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Malta |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Malta |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Malta |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Netherlands |
|
Diovan 40 |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Netherlands |
|
Diovan 80 |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Netherlands |
|
Diovan 160 |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Netherlands |
|
Diovan 320 |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Norway |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Norway |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Norway |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Norway |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Poland |
|
Diovan |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Poland |
|
Diovan |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Poland |
|
Diovan |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Poland |
|
Diovan |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Portugal |
|
Diovan |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Portugal |
|
Diovan |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Portugal |
|
Diovan g |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Portugal |
|
Diovan |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Romania |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Romania |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Romania |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Slovak Republic |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Slovak Republic |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Slovak Republic |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Slovak Republic |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Slovak Republic |
|
Diovan 80 mg |
80 mg |
Hard gelatine capsules |
Oral |
||||||
|
Slovak Republic |
|
Diovan 160 mg |
160 mg |
Hard gelatine capsules |
Oral |
||||||
|
Slovenia |
|
Diovan 40 mg filmsko obložene tablete |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Slovenia |
|
Diovan 80 mg filmsko obložene tablete |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Slovenia |
|
Diovan 160 mg filmsko obložene tablete |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Slovenia |
|
Diovan 320 mg filmsko obložene tablete |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Diovan Cardio 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Kalpress Cardio 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Miten Cardio 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Diovan 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Kalpress 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Miten 80 mg |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Diovan 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Kalpress 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Miten 160 mg |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Kalpress 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Spain |
|
Miten 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Diovan |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Angiosan |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Valsartan Novartis |
40 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Diovan |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Angiosan |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Valsartan Novartis |
80 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Diovan |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Angiosan |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Valsartan Novartis |
160 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Diovan |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Angiosan |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Valsartan Novartis |
320 mg |
Film-coated tablets |
Oral |
||||||
|
Sweden |
|
Diovan |
80 mg |
Hard gelatine capsules |
Oral |
||||||
|
Sweden |
|
Diovan |
160 mg |
Hard gelatine capsules |
Oral |
||||||
|
United Kingdom |
|
Diovan 40 mg |
40 mg |
Film-coated tablets |
Oral |
||||||
|
United Kingdom |
|
Diovan 320 mg |
320 mg |
Film-coated tablets |
Oral |
||||||
|
United Kingdom |
|
Diovan 40 mg |
40 mg |
Hard gelatine capsules |
Oral |
||||||
|
United Kingdom |
|
Diovan 80 mg |
80 mg |
Hard gelatine capsules |
Oral |
||||||
|
United Kingdom |
|
Diovan 160 mg |
160 mg |
Hard gelatine capsules |
Oral |
V Announcements
ADMINISTRATIVE PROCEDURES
Commission
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/41 |
MEDIA 2007 — DEVELOPMENT, DISTRIBUTION, PROMOTION AND TRAINING
Call for proposals — EACEA/03/09
Support for the transnational distribution of European films — The ‘Automatic’ Scheme 2009
(2009/C 73/05)
1. Objectives and description
This notice of a call for proposals is based on Decision No 1718/2006/EC of the European Parliament and of the Council of 15 November 2006 concerning the implementation of a programme of support for the European audiovisual sector (MEDIA 2007).
One of the objectives of the programme is to encourage and support the wider transnational distribution of recent European films by providing funds to distributors, based upon their performance on the market, for further reinvestment in new non-national European films.
The scheme also aims to encourage the development of links between the production and distribution sectors thus improving the market share of European films and the competitiveness of European companies.
2. Eligible applicants
This notice is aimed at European companies specialised in the theatrical distribution of European works and whose activities contribute to the attainment of the above objectives of the MEDIA programme as described in the Council Decision.
Applicants must be established in one of the following countries:
|
— |
the 27 countries of the European Union, |
|
— |
the EFTA countries, |
|
— |
Switzerland, |
|
— |
Croatia. |
3. Eligible actions
The ‘automatic’ support scheme works in two phases:
|
— |
generation of a potential Fund, proportional to the number of paying admission tickets sold for non-domestic European films in States participating in the Programme, up to a fixed ceiling per film and adjusted for each country, |
|
— |
reinvestment of the potential Fund: thus generated by each company, the Fund must be reinvested in 3 modules (3 types of action) by 1 October 2010:
|
Action type 1 & 2:
|
|
The maximum duration of the actions is 30 months. |
|
|
The actions have to start on 1 August 2009 and finish on 1 February 2012. |
Action type 3:
|
|
The maximum duration of the actions is 42 months. |
|
|
The actions have to start on 1 February 2009 and finish on 1 August 2012. |
4. Award criteria
A potential Fund will be attributed to eligible European distribution companies on the basis of the admissions achieved by the European non-national films distributed by the applicant in the reference year (2008). Within the limit of the budgetary resources available, the potential Fund will be calculated based upon a fixed amount per eligible entry.
The support will take the form of a potential Fund (the ‘Fund’) available to distributors for further investments in recent non-national European films.
The Fund can be reinvested:
|
1. |
in the production of new non-national European films (i.e. films not yet completed at the date of application for reinvestment); |
|
2. |
in the meeting of Minimum Distribution Guarantees for recent non-national European films; |
|
3. |
in the meeting of distribution costs i.e. P&A (promotion and advertising) for recent non-national European films. |
5. Budget
The total budget available is EUR 17 000 000.
There is no maximum amount.
The financial contribution awarded is a subsidy. The financial support from the Commission cannot exceed 40 %, 50 % or 60 % of the total eligible costs.
The Agency reserves the right not to allocate all the funds available.
6. Deadline for submission of applications
Proposals for the ‘generation’ of a potential Fund must be sent (postmark date) on 29 May 2009 at the latest and at the following address:
|
Education, Audiovisual and Culture Executive Agency (EACEA) |
|
Constantin Daskalakis — BOUR 3/66 |
|
Avenue du Bourget, 1 |
|
1140 Brussels |
|
BELGIUM |
Only applications submitted on the official application form, duly signed by the person entitled to enter into legally binding commitments on behalf of the applicant organisation will be accepted. Envelopes must clearly mention:
MEDIA 2007 — DISTRIBUTION EACEA/03/09 — AUTOMATIC CINEMA
Applications sent by fax or e-mail will be rejected.
7. Full details
The full detailed guidelines together with the application forms can be found at the following Internet address:
http://ec.europa.eu/information_society/media/distrib/schemes/auto/index_en.htm
Applications must comply with all terms of the guidelines, be submitted on the forms provided and containing all the information and annexes specified in the full text of the call.
PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY
Commission
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/43 |
Notice by the Ministry of the Economy of the Republic of Latvia of a call for tenders for hydrocarbon exploration and production within the exclusive economic zone of the Republic of Latvia
(2009/C 73/06)
Pursuant to the Law on Substrata, Cabinet Regulation No 597 of 4 September 2007 on hydrocarbon prospection, exploration and production and the amounts of and procedures for paying Government duties, and Cabinet Order No 594 of 21 September 2007 on establishing licensed hydrocarbon prospection sites within the exclusive economic zone of the Republic of Latvia, the Ministry of the Economy of the Republic of Latvia hereby gives notice of a call for tenders for hydrocarbon exploration and production in the exclusive economic zone of the Republic of Latvia within the following ellipsoidal (geographical) coordinates under the WGS 84 system:
|
Corner points |
Latitude N |
Longitude E |
|
1 |
56°10′00″ |
19°10′14,5″ |
|
2 |
56°14′59,1″ |
19°13′22,8″ |
|
3 |
56°26′59,2″ |
19°20′52,7″ |
|
4 |
56°30′00″ |
19°22′23″ |
|
5 |
56°30′00″ |
19°40′00″ |
|
6 |
56°10′00″ |
19°40′00″ |
Pursuant to Article 3(2) of Directive 94/22/EC of the European Parliament and of the Council of 30 May 1994 on the conditions for granting and using authorizations for the prospection, exploration and production of hydrocarbons and paragraph 46 of the aforementioned Cabinet Regulation, the Ministry of the Economy invites all interested entities to obtain a copy of the regulations relating to the call for tenders for hydrocarbon prospection and production within the exclusive economic zone of the Republic of Latvia.
Type of licence: The successful tenderer will be issued with a hydrocarbon prospection and production licence.
Address and office hours for obtaining tender regulations: Ministry of the Economy of the Republic of Latvia, Brīvības iela 55, Riga, LV-1519, every weekday from 9 a.m. to 5 p.m. (GMT +2). The tender regulations may be obtained within 30 days of the date of publication of this notice.
Cost of obtaining the tender regulations: LVL 350. Payment must be made in LVL by transfer of funds to the Ministry of the Economy of the Republic of Latvia, registration no 90000086008, Treasury, code TRELLV22, account no LV10TREL212001C310000, indicating that it is ‘Payment for tender regulations in relation to the call for tenders for hydrocarbon prospection and production within the exclusive economic zone of the Republic of Latvia’. To obtain the regulations, proof of payment must be presented.
Deadline for applications: A tender may be submitted in person at the Customer Service Centre of the Ministry of the Economy of the Republic of Latvia, or may be sent by mail to the Ministry of the Economy of the Republic of Latvia, Brīvības iela 55, Riga, LV-1519 within 90 days of the date of publication of this notice. The deadline for submission of applications is 5 p.m. (GMT +2) on the ninetieth day following the date of publication of this notice.
Contact person: Ilze Ruško, Head of the Licence, Permit and Coordination Division, Department of Energy, Ministry of the Economy of the Republic of Latvia, tel. +371 67013173, e-mail: ilze.rusko@em.gov.lv. Please apply for the tender regulations prior to submitting your application.
OTHER ACTS
Commission
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/45 |
Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs
(2009/C 73/07)
This publication confers the right to object to the application pursuant to Article 7 of Council Regulation (EC) No 510/2006 (1). Statements of objection must reach the Commission within six months from the date of this publication.
SUMMARY
COUNCIL REGULATION (EC) No 510/2006
‘ČERNÁ HORA’
EC No: CZ-PGI-0005-0409-19.10.2004
PDO ( ) PGI ( X )
This summary sets out the main elements of the product specification for information purposes.
1. Responsible department in the Member State:
|
Name: |
Úřad průmyslového vlastnictví |
|||
|
Address: |
|
|||
|
Tel. |
+420 220383111 |
|||
|
Fax |
+420 224324718 |
|||
|
E-mail: |
posta@upv.cz |
2. Group:
|
Name: |
Pivovar Černá Hora, a. s. |
|||
|
Address: |
|
|||
|
Tel. |
+420 516482411 |
|||
|
Fax |
+420 516437201 |
|||
|
E-mail: |
ekonom@pivovarch.cz |
|||
|
Composition: |
Producers/processors ( X ) Other ( ) |
This application derogates from Article 5(1) of Regulation (EC) No 510/2006 on account of the fact that there is only one producer in the area. The requirements laid down in Article 2 of Commission Regulation (EC) No 1898/2006 are fulfilled.
3. Type of product:
Class 2.1: Beer
4. Specification:
(Summary of requirements under Article 4(2) of Regulation (EC) No 510/2006)
4.1. Name:
‘Černá Hora’
4.2. Description:
The light beer is medium to highly attenuated, golden yellow to golden brown in colour, good head with strong bite, medium to full-favoured, with a clean flavour of malt and hops, and hoppy aroma. The fullness of flavour is mainly due to the presence of unfermented residual extract, characterised by a difference between apparent and real attenuation. A very faint yeasty or fruity (ester) taste and aroma is permitted. The low intensity of the whole aroma is indicative of the relatively low content of unwanted fermentation by-products. The beer is medium to high in bitterness, and has a slight to mild harshness, with longer finish.
The dark beer is medium to highly attenuated, reddish to red-brown in colour with good head, pleasantly hoppy taste and aroma. It has a medium bite and a typically full flavour, owing to the difference between apparent and real attenuation and to the unfermentable compounds in the raw materials. Caramel and treacle are admissible by-flavours.
Varieties of beer and the sensory characteristics thereof:
The Světlý ležák (light lager) is medium to highly attenuated, golden yellow to golden brown in colour, good head with strong bite, medium-favoured, with clean flavour of malt and hops and a hoppy aroma. A very faint yeasty or fruity (ester) taste and aroma is permitted. The beer is of medium bitterness, and has a slight harshness, with longer finish.
The Světlé výčepní pivo (light draught beer) is medium to highly attenuated, golden yellow to golden brown in colour, good head with strong bite, full-favoured, with a clean flavour of malt and a hoppy aroma. A very faint yeasty or fruity (ester) taste and aroma is permitted. The beer is high in bitterness, moderately harsh, with a longer finish.
The Nefiltrované výčepní pivo (unfiltered draught beer) is characterised by a good head, golden yellow to golden brown colour, good bite and fullness of flavour, and by a yeasty flavour and aroma. The beer has a significant, moderately harsh, hoppy bitterness, leaving behind a feeling of pleasant, gradually diminishing bitterness, without any hint of harshness or astringency.
The Tmavý ležák (dark lager) is a beer with the addition of caramel and coloured malt, medium attenuated, garnet to red-brown in colour, caramel to sweetish taste with delicate bitterness.
The Polotmavé výčepní pivo (semi-dark draught beer) is medium to highly attenuated, reddish to garnet colour, strong bite, pleasantly hoppy and with a moderately caramel aroma and flavour with good head.
All types of ‘Černá Hora’ beer are low-fermentation beers characterised by particular sensory qualities, especially unique aroma and flavour with strong bite.
Light beer — quality benchmarks:
|
|
Pale lager |
Pale draught |
Unfiltered pale draught |
|
|
Original gravity |
(% by weight) |
11,00-12,99 |
8,00-10,99 |
8,00-10,99 |
|
Alcohol |
(% by volume) |
3,8-6,0 |
3,5-4,5 |
3,5-4,5 |
|
Colour |
EBC units |
8,0-16,0 |
7,0-16,0 |
7,8-16,0 |
|
Bitter substances |
EBC units |
20,0-45,0 |
16,0-28,0 |
16,0-28,0 |
|
pH |
|
4,2-4,9 |
4,3-4,7 |
4,3-4,7 |
|
Difference between apparent and real attenuation |
(% rel.) |
1,0-10,0 |
1,0-10,0 |
1,0-10,0 |
|
Polyphenols |
(mg/l) |
130,0-230,0 |
130,0-230,0 |
130,0-230,0 |
Dark beer, semi-dark beer — quality benchmarks:
|
|
Dark lager |
Semi-dark draught |
|
|
Original gravity |
(% by weight) |
11,00-12,99 |
8,00-10,99 |
|
Alcohol |
(% by volume) |
3,6-5,7 |
3,5-4,5 |
|
Colour |
EBC units |
50,0-120,0 |
16,0-40,0 |
|
Bitter substances |
EBC units |
20,0-45,0 |
16,0-28,0 |
|
pH |
|
4,1-4,8 |
4,3-4,7 |
|
Difference between apparent and real attenuation |
(% rel.) |
1,0-10,0 |
1,0-10,0 |
|
Polyphenols |
(mg/l) |
130,0-230,0 |
130,0-230,0 |
Raw materials:
Barley malt
This is a light malt, known as ‘Czech malt’, which is produced from two-row spring barley. This barley malt is characterised by low solubility and fermentation.
The following table shows Congress Wort values produced from barley malt:
|
Extract in dry malt |
(% by weight) |
min. |
80 % |
|
Kolbach index |
(%) |
|
37-41 % |
|
Diastatic power |
(WK units) |
min. |
220 |
|
Actual attenuation |
(%) |
max. |
82 % |
|
Friability |
(%) |
min. |
75 % |
Hops
This is the Žatecký poloraný červeňák variety. These hops are highly specific: they differ primarily from other hop varieties in their ratio of alpha to beta-bitter acids and in their beta-farnesene content. Either dried hops or hop extract is used. (Keep the original wording, where the Žatecký poloraný červeňák variety rather than SKVN Žatecký chmel is used for the preparation of beer).
Water
Water from a variety of sources is used in the production of ‘Černá Hora’ beer. In terms of hardness, this water is considered soft to medium-hard.
Brewer's yeast
Bottom-fermenting yeast strains (Saccharomyces cerevisiae subs. uvarum) are used for producing ‘Černá Hora’ beer as they offer the requisite difference between apparent and real attenuation under this specification.
4.3. Geographical area:
The municipality of ‘Černá Hora’ in Southern Moravia, Czech Republic.
4.4. Proof of origin:
The applicant for registration of the geographical designation ‘Černá Hora’ keeps a register of suppliers of raw materials and a register of buyers of the finished product. For each product, compulsory data on products, including addresses, are provided, thereby enabling product traceability.
The entire beer production technology is continuously monitored. The implementation and results of checks are continuously recorded. All raw materials brought in for producing beer are also subject to quality control. Water quality is checked for microbiological suitability and is regularly controlled. A written record of all checks is kept. A record is also kept of the individual batches of raw materials used in the production of individual batches of beer.
Compliance with the specifications is monitored by the Czech Agriculture and Food Inspection Authority.
4.5. Method of production:
‘Černá Hora’ beer is produced solely by means of the double mash decoction process. Bitter wort is cooked depending on the beer's original gravity. The process of primary fermentation takes place separately from that of the maturing of the beer. This is classic production without intensification processes.
Beer production begins in the brewing house. After mixing the ground malt with the water, just a third of the volume is gradually warmed. This enables the starch and other substances of the malt extract to be transferred into the solution and the starch to be split. The mashing process is repeated twice, and each mash is warmed separately. After the mashing out process, the residue of the malt culms is separated out, giving rise to the first portion of wort. The culm is then drained off with hot water and the digest is mixed with the first portion of wort. The resulting wort is heated for 80 to 120 minutes with separately batched hops or hop products to obtain a hopped wort. Each brew is heated at the original concentration of the wort corresponding to the required gravity of the beer. In other words, during further production, the gravity of the beer is not altered.
The heated wort is then cooled to fermentation temperature, brewer's yeast is added, in particular bottom-fermenting yeast strains, and the first, and indeed main, stage of beer fermentation takes place. This main fermentation stage takes place in classic, open fermenting rooms. The main fermentation temperature must not exceed 9,5 °C. The main fermentation takes 6 to 12 days, depending on the gravity of the original wort.
After the completion of main fermentation comes the lagering stage. This takes place at lower temperatures than the main fermentation stage, as low as around 0 °C and under moderate excess pressure in closed tanks. The lagering process takes 21 to 60 days, depending on the gravity of the beer. During this stage, the beer becomes clear, is saturated with carbon dioxide, and its flavour is rounded off. This gives the beer bite, with a dense, firm head. During the lagering stage, the striking flavour and yeasty smell disappears, the bitterness softens and the aroma typical of certain types of beer emerges. After the completion of the lagering process, the beer is filtered immediately without first altering the original gravity and transferred into barrels, bottles and, where applicable, cans or tanks. Unfiltered beer is also permitted. The end product must satisfy the quality benchmarks set out in the tables in Section 4.2 of this summary.
4.6. Link:
The beer for which registration of designation of origin of the term ‘Černá Hora’ has been requested has been produced continuously in the municipality of ‘Černá Hora’ since the 13th century. The first written record of the brewery in ‘Černá Hora’ dates back to 1530.
Since then, there has been a rich history of breweries and beer making in ‘Černá Hora’. Many owners have come and gone, but the production and quality of ‘Černá Hora’ beer has steadily increased. In 1949, the brewery was nationalised and gradually incorporated into various national firms. The production of ‘Černá Hora’ nevertheless went on uninterrupted, following traditional production methods and processes. In 1996 the brewery became independent as part of a privatisation drive.
Records of the brewery's rich history and beer production in ‘Černá Hora’ are contained in many documents stored in the Moravian national archive in Brno (for example, the Dominican era in ‘Černá Hora’, the Josefinsky estate for the municipalities of ‘Černá Hora’ and Bořitov and land transfer registry for the municipalities of ‘Černá Hora’ and Bořitov etc) and also in the archives of the Pivovar Černá Hora, a.s. (Černá Hora brewery).
With the development of the brewery, beer production increased and the buildings and production equipment were expanded and modernised accordingly. These changes had only a minor effect on the uniqueness of ‘Černá Hora’ beer, which can ultimately be considered a beverage derived from a centuries-old tradition. All ‘Černá Hora’ brewers have endeavoured to protect the historic uniqueness of ‘Černá Hora’ beer, which has been only minimally affected over time.
Testament to the quality of ‘Černá Hora’ beer and its popularity is the many prizes it has won in domestic and international competitions and fairs (for example, the Táborský palcát (Tabor mace), Cena českých sládků (Czech brewers' prize), Pivo spanilých jízd (Beer of the Hussite campaigns), Zlatý pohár Pivex (Pivex golden cup) and Česká pivní pečeť (Czech beer seal)).
The fame and popularity of ‘Černá Hora’ beer is also evidenced by the fact that in the municipality of ‘Černá Hora’ a wide-ranging cultural and social event to present the beer produced there has been held every spring and autumn for the last ten years. In April, it is the Vítání jara (APRÝLES) (Spring Welcome) and in September the Pivní pouť (Beer fair). These events regularly attract several thousand visitors, who come not just from around Černá Hora but from all over the Czech Republic, and indeed abroad.
Beer from Černá Hora is also mentioned in various encyclopaedias, for example Verhoef, Berry: Large Encyclopaedia of Beer, Čestlice, Rebo Productions, 2002; Jackson, Michael: Great Beer Guide, Prague, Fortuna Print, 2001. Many articles have also been written and published about it in national and local newspapers and magazines. In Černá Hora itself, the periodical ‘Černohorský máz’ is published, which among other things provides information on the successes of ‘Černá Hora’ beer in various competitions and fairs.
In 1995 the Brno historian Leoš Vašek wrote about ‘Černá Hora’ beer in his 1995 book ‘V ČERNÉ HOŘE PIVA MOŘE — z historie černohorského pivovarnictví’ (IN ČERNA HORA A SEA OF BEER — on the history of the Černá Hora brewery).
4.7. Inspection body:
|
Name: |
Státní zemědělská a potravinářská inspekce, inspektorát v Brně |
|||
|
Address: |
|
|||
|
Tel. |
+420 542424011 |
|||
|
Fax |
+420 542426717 |
|||
|
E-mail: |
epodatelna@szpi.gov.cz |
4.8. Description:
—
(1) OJ L 93, 31.3.2006, p. 12.
Corrigenda
|
27.3.2009 |
EN |
Official Journal of the European Union |
C 73/50 |
Corrigendum to authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections
( Official Journal of the European Union C 62 of 17 March 2009 )
(2009/C 73/08)
On page 11, against ‘Reference number of the aid’:
for:
‘N 23/08’,
read:
‘N 23/09’.